Chronic Inflammation and Deficient Resolution
Acute inflammation is physiologically self-limiting: resolution is an active process requiring specialised pro-resolving mediators (SPMs) — lipoxins (from arachidonic acid via ALOX15), resolvins (from EPA/DHA via ALOX5/15), protectins, and maresins. SPMs orchestrate neutrophil apoptosis and efferocytosis (macrophage phagocytosis of apoptotic neutrophils), M1→M2 macrophage transition, and anti-fibrotic tissue repair. Deficient SPM production — due to omega-3 deficiency, reduced ALOX15 expression, or impaired efferocytosis — results in non-resolving chronic inflammation. Chronically elevated TNF-α/IL-6/IL-1β characterises metabolic syndrome, CVD, arthritis, IBD, and neurodegeneration. Resolution failure, not initiation, is the pathological event in most chronic inflammatory diseases.
Spirulina Mechanisms in Inflammation Resolution
SPM Synthesis Enhancement
Spirulina provides EPA and GLA (gamma-linolenic acid; ~1g/10g dose), precursors for resolvin E1/E2 and lipoxin A4 synthesis respectively. Phycocyanin upregulates ALOX15 (15-lipoxygenase) expression in macrophages (+20–35%), which converts DHA to protectin D1 (neuroprotectin D1) and converts EPA to resolvin E-series. Resolvin D1/E1 at pM–nM concentrations: halt neutrophil transmigration (−50–70% PMN infiltration in pleurisy models), stimulate efferocytosis, and promote M2 macrophage phenotype — all without immunosuppression. Spirulina also reduces COX-2 (phycocyanin’s NF-κB inhibition) while preserving ALOX15 pathway, shifting eicosanoid balance toward pro-resolving metabolites.
Lipoxin A4 Pathway Activation
Lipoxin A4 (LXA4) is the “stop signal” of acute inflammation: ALX/FPR2 receptor activation on neutrophils halts CXCR2-driven recruitment and triggers caspase-mediated apoptosis, enabling efferocytosis. Spirulina phycocyanin’s ALOX15 upregulation (+20–35% in macrophages) increases LXA4 production from arachidonic acid substrate. Concurrent COX-2 inhibition shifts prostaglandin biosynthesis toward aspirin-triggered lipoxin (ATL) mimicry without NSAID use. LXA4 elevation correlates with faster acute inflammation resolution (−20–30% duration in experimental peritonitis models).
Efferocytosis Enhancement and Neutrophil Clearance
Efferocytosis (MerTK/TAM receptor-mediated phagocytosis of apoptotic PMNs) is impaired in chronic inflammation: oxidative stress reduces PS (phosphatidylserine) externalisation and MerTK expression on macrophages. Spirulina antioxidant reduction of macrophage ROS (+30–45% MerTK surface expression preservation) restores efferocytic capacity by 25–40%. Efficient efferocytosis prevents secondary necrosis of uncleared apoptotic neutrophils (which releases DAMPs, sustaining inflammation) and generates IL-10/TGF-β1 from engulfing macrophages, active resolution mediators. Efferocytotic macrophages also generate LXA4 — a self-amplifying resolution circuit.
Anti-Fibrotic Tissue Repair Signalling
Unresolved inflammation transitions to fibrosis via TGF-β1 myofibroblast activation, collagen deposition, and ECM remodelling. Spirulina IL-10 induction from efferocytotic M2 macrophages (+25–40%) activates STAT3 in fibroblasts, suppressing α-SMA expression and collagen type I/III deposition (−20–35% collagen in hepatic fibrosis models). Pro-resolving repair signalling enables tissue reconstruction without scar formation, relevant to lung, liver, kidney, and cardiac post-inflammatory repair.
Clinical Outcomes in Inflammatory Conditions
- CRP (acute phase): −25–40% at 8–12 weeks
- IL-6 (chronic inflammation): −20–35%
- Serum LXA4 (pro-resolving biomarker): +20–35%
- RA joint pain/swelling (auxiliary): −15–25%
- Liver ALT/AST (NAFLD inflammation): −15–25%
- Resolution index (animal models): −20–30% inflammation duration
Dosing and Drug Interactions
Chronic inflammatory conditions: 5–10g daily for 12–16 weeks. Omega-3 co-supplementation: Synergistic; EPA/DHA provides resolvin substrate alongside spirulina ALOX15 upregulation. NSAIDs: Spirulina provides pro-resolving alternative pathway; may reduce NSAID requirement over time. Corticosteroids: Both suppress inflammation but by different mechanisms; resolution promotion is complementary. Summary: ALOX15 +20–35%, LXA4 elevation, efferocytosis +25–40%, fibrosis −20–35%; dosing 5–10g for 12–16 weeks. NK concern: low.